.gif)
Daiichi Sankyo Company, Limited's generics subsidiary, Daiichi Sankyo Espha, will launch seven new generic drugs with four new active ingredients. The products: Naftopidil OD tablets 25mg, 50mg, 75mg “DSEP” (Flivas OD tablets 25mg, 50mg, 75mg) for the treatment for urination disorder due to enlargement of prostate; Metformin hydrochloride tablets 250mgMT, 500mgMT “DSEP” (Metgluco tablets 250mg, 500mg) for biguanide-type oral hypoglycemic agent; Letrozole tablets 2.5mg “DSEP” (Femara tablets 2.5mg) Aromatase inhibitor/postmenopausal breast cancer treatment; Oxaliplatin IV infusion solution 200mg “DSEP” (Elplat IV infusion solution 200mg) anti-malignant tumour agent.
In order to respond to the risk of patient family members, particularly children, taking their medicine by mistake, a new measure has been introduced for Letrozole tablets (postmenopausal breast cancer treatment).
Daiichi Sankyo Espha is a company that manufactures and markets generic drugs, accommodating rising demand based on the spirit of Daiichi Sankyo Group corporate philosophy of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha has continued to maintain a level of quality based on the quality management standards of the Daiichi Sankyo Group.
Daiichi Sankyo Espha has contributed to innovations in formulation and labeling to make drugs easier to ingest and harder for patients to mistakenly or incorrectly take. These kind of high value-added generic drugs are put forth by Daiichi Sankyo Espha as “premium generics.”
Subscribe to PharmaTutor News Alerts by Email >>
